← All Karyopharm Therapeutics INC filings

Karyopharm Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KPTI
Karyopharm Therapeutics INC
10-K: Karyopharm Therapeutics Faces Going Concern Uncertainty Despite XPOVIO Revenue
Karyopharm Therapeutics reports its 10-K filing, highlighting ongoing financial challenges and substantial doubt about its ability to continue as a going concern despite revenue from its drug XPOVIO.
NASDAQ
KPTI
Karyopharm Therapeutics INC
10-K: Karyopharm Therapeutics Inc. Navigates Complex Financial Landscape in 2023 Annual Report
Karyopharm Therapeutics Inc.'s 2023 annual report reveals a year of strategic shifts, financial adjustments, and continued focus on its core oncology programs.